Form 6-K — CureVac N.V.: Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of January, 2022, Commission File Number 001-39446. It states that on January 3, 2022 the company issued its Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021, furnished as Exhibit 99.1. The report says the information is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-01-03-0001104659-22-000405-86794c16aa/
, SHA-256 b73f3d7841a9c50f05b1a664fc67a7050fed0754dc05da20b4a043b9e71a003f.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On January 3, 2022, CureVac N.V. (the “Company”) issued the Company’s Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021. The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: January 3, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021
File and source
- File
- SEC_CVAC_6-K_filed2022-01-03_0001104659-22-000405.htm
- Size
- 12,946 bytes
- SHA-256
- b73f3d7841a9c50f05b1a664fc67a7050fed0754dc05da20b4a043b9e71a003f
- Original
- www.sec.gov